NEJM report of 2 SLE pts treated w/ Daratumumab (anti-CD38) to deplete plasma cells a life-threatening refractory SLE. Clinical improvement associated w/ depletion of plasma cells, reduced IFN type I activity, down-regulation of T-cell transcripts https://t.co/K0fwpEHS81